Immunological Evasion in Glioblastoma

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Maganã Maldonado, Roxana ^a   Chávez Cortez, Elda Georgina ^a   Olascoaga Arellano, Nora Karen ^a   López Mejiá, Mariana ^a   Maldonado Leal, Fernando Manuel ^a   Sotelo, Julio ^a   Pineda, Benjamín ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; PERTUSSIS TOXIN; TEMOZOLOMIDE; CYTOKINE;

CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; GLIOBLASTOMA; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MICROGLIA; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; BIOLOGICAL MODEL; BRAIN; BRAIN TUMOR; IMMUNOLOGY; INNATE IMMUNITY; MONONUCLEAR CELL; TUMOR ESCAPE;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CYTOKINES; GLIOBLASTOMA; HUMANS; IMMUNITY, INNATE; LEUKOCYTES, MONONUCLEAR; MODELS, IMMUNOLOGICAL; TUMOR ESCAPE;

EID: 84973349066     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/7487313     Document Type: Review

References (86)

1. R. Siegel,D. Naishadham,A. Jemal, "Cancer statistics, 2013," CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11-30, 2013.
2. M. A. Lopez-Gonzalez and J. Sotelo, "Brain tumors in Mexico: characteristics and prognosis of glioblastoma," Surgical Neurology, vol. 53, no. 2, pp. 157-162, 2000.
3. L. Velásquez-Pérez and M. E. Jiménez-Marcial, "Clinicalhistopathologic concordance of tumors of the nervous system at the Manuel Velasco Suárez National Institute of Neurology and Neurosurgery in Mexico City," Archives of Pathology and Laboratory Medicine, vol. 127, no. 2, pp. 187-192, 2003.
4. D. A. Mitchell, X. Cui, R. J. Schmittling et al., "Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans," Blood, vol. 118, no. 11, pp. 3003-3012, 2011.
5. J. C. Buckner, "Factors influencing survival in high-grade gliomas," Seminars in Oncology, vol. 30, no. 6, supplement 19, pp. 10-14, 2003.
6. R. Stupp, W. P. Mason, M. J. VanDen Bent et al., "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma," The New England Journal of Medicine, vol. 352, no. 10, pp. 987-996, 2005.
7. M. D. Vesely,M. H. Kershaw, R. D. Schreiber, M. J. Smyth, "Natural innate and adaptive immunity to cancer," Annual Review of Immunology, vol. 29, no. 1, pp. 235-271, 2011.
8. V. S. Akopian, A. V. Bol'shunov, Iu. V. Pereslegin, "Optical laser interventions on the anterior portion of the eye," Vestnik Oftalmologii, no. 4, pp. 29-35, 1978.
9. Y. Sawamura and N. de Tribolet, "Immunobiology of brain tumors," Advances and Technical Standards inNeurosurgery, vol. 17, pp. 3-64, 1990.
10. J. Goldmann, E. Kwidzinski, C. Brandt, J. Mahlo, D. Richter, I. Bechmann, "T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa," Journal of Leukocyte Biology, vol. 80, no. 4, pp. 797-801, 2006.
11. L. M. Wakim, A. Woodward-Davis, R. Liu et al., "Themolecular signature of tissue resident memory CD8 T cells isolated from the brain," The Journal of Immunology, vol. 189, no. 7, pp. 3462-3471, 2012.
12. D. Stavrou, A. P. Anzil, W. Weidenbach, H. Rodt, "Immunofluorescence study of lymphocytic infiltration in gliomas. Identification of T-lymphocytes," Journal of the Neurological Sciences, vol. 33, no. 1-2, pp. 275-282, 1977.
13. Y. Sawamura,H. Abe,T. Aida,M. Hosokawa,H. Kobayashi, "Isolation and in vitro growth of glioma-infiltrating lymphocytes, an analysis of their surface phenotypes," Journal of Neurosurgery, vol. 69, no. 5, pp. 745-750, 1988.
14. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., "The 2007WHO classification of tumours of the central nervous system," Acta Neuropathologica, vol. 114, no. 2, pp. 97-109, 2007.
15. T. Morimura, C. Neuchrist, K. Kitz et al., "Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation," Acta Neuropathologica, vol. 80, no. 3, pp. 287-294, 1990.
16. R. Kiefer, M. L. Supler, K. V. Toyka, W. J. Streit, "In situ detection of transforming growth factor-mRNA in experimental rat glioma and reactive glial cells," Neuroscience Letters, vol. 166, no. 2, pp. 161-164, 1994.
17. J. J. Watters, J. M. Schartner, B. Badie, "Microglia function in brain tumors," Journal of Neuroscience Research, vol. 81, no. 3, pp. 447-455, 2005.
18. J. F. Curtin, M. Candolfi, T. M. Fakhouri et al., "Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials," PLoS ONE, vol. 3, no. 4,Article ID e1983, 2008.
19. G. Kroemer, L. Galluzzi, O. Kepp, L. Zitvogel, "Immunogenic cell death in cancer therapy," Annual Review of Immunology, vol. 31, pp. 51-72, 2013.
20. D. R. Fooksman, S. Vardhana, G. Vasiliver-Shamis et al., "Functional anatomy of T cell activation and synapse formation," Annual Review of Immunology, vol. 28, pp. 79-105, 2010.
21. P. Guermonprez, J. Valladeau, L. Zitvogel, C. Théry, S. Amigorena, "Antigen presentation and T cell stimulation by dendritic cells," Annual Review of Immunology, vol. 20, pp. 621-667, 2002.
22. A. Nimmerjahn, F. Kirchhoff, F. Helmchen, "Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo," Science, vol. 308, no. 5726, pp. 1314-1318, 2005.
23. F. Aloisi, R. De Simone, S. Columba-Cabezas, G. Penna, L. Adorini, "Functional maturation of adult mouse resting microglia into anAPC is promoted by granulocyte-macrophage colony-stimulating factor and interaction with Th1 cells," The Journal of Immunology, vol. 164, no. 4, pp. 1705-1712, 2000.
24. G. Stollg and S. Jander, "The role ofmicroglia and macrophages in the pathophysiology of the CNS," Progress in Neurobiology, vol. 58, no. 3, pp. 233-247, 1999.
25. S. Brandenburg, A. Müller, K. Turkowski et al., "Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative proangiogenic factors," Acta Neuropathologica, vol. 131, no. 3, pp. 365-378, 2016.
26. A. Facoetti, R. Nano, P. Zelini et al., "Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors," Clinical Cancer Research, vol. 11, no. 23, pp. 8304-8311, 2005.
27. A. M. Kostianovsky, L. M. Maier, R. C.,erson, J. N. Bruce, D. E.,erson, "Astrocytic regulation of human monocytic/microglial activation," The Journal of Immunology, vol. 181, no. 8, pp. 5425-5432, 2008.
28. B. Badie, J. Schartner, S. Prabakaran, J. Paul, J. Vorpahl, "Expression of Fas ligand by microglia: possible role in glioma immune evasion," Journal of Neuroimmunology, vol. 120, no. 1-2, pp. 19-24, 2001.
29. J. C. Rodrigues, G. C. Gonzalez, L. Zhang et al., "Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties," Neuro-Oncology, vol. 12, no. 4, pp. 351-365, 2010.
30. B. Tang,W. Wu,X. Wei,Y. Li, G. Ren,W. Fan, "Activation of glioma cells generates immune tolerant NKT cells," The Journal of Biological Chemistry, vol. 289, no. 50, pp. 34595-34600, 2014.
31. K. M. Dhodapkar, B. Cirignano, F. Chamian et al., "Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cellmediated expansion," International Journal of Cancer, vol. 109, no. 6, pp. 893-899, 2004.
32. N. A. Charles, E. C. Holland, R. Gilbertson, R. Glass, H. Kettenmann, "The brain tumor microenvironment," Glia, vol. 60, no. 3, pp. 502-514, 2012.
33. M. K. Bhondeley, R. D. Mehra, N. K. Mehra et al., "Imbalances in T cell subpopulations in human gliomas," Journal of Neurosurgery, vol. 68, no. 4, pp. 589-593, 1988.
34. R. M. Prins, G. P. Scott, R. E. Merchant, M. R. Graf, "Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression," Cancer Immunology, Immunotherapy, vol. 51, no. 4, pp. 190-199, 2002.
35. A. M. Sonabend, C. E. Rolle, M. S. Lesniak, "The role of regulatory T cells in malignant glioma," Anticancer Research, vol. 28, no. 2, pp. 1143-1150, 2008.
36. L. M. DeAngelis, "Brain tumors," The New England Journal of Medicine, vol. 344, no. 2, pp. 114-123, 2001.
37. Y. Wu, M. Borde, V. Heissmeyer et al., "FOXP3 controls regulatory T cell function through cooperation with NFAT," Cell, vol. 126, no. 2, pp. 375-387, 2006.
38. M. J. Riemenschneider and G. Reifenberger, "Astrocytic tumors," Recent Results in Cancer Research, vol. 171, pp. 3-24, 2009.
39. A. B. Heimberger, M. Abou-Ghazal, C. Reina-Ortiz et al., "Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas," Clinical Cancer Research, vol. 14, no. 16, pp. 5166-5172, 2008.
40. P. E. Fecci, D. A. Mitchell, J. F. Whitesides et al., "Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma," Cancer Research, vol. 66, no. 6, pp. 3294-3302, 2006.
41. D. A. Wainwright, P. Nigam, B. Thaci,M. Dey,M. S. Lesniak, "Recent developments on immunotherapy for brain cancer," Expert Opinion on Emerging Drugs, vol. 17, no. 2, pp. 181-202, 2012.
42. A. E. L.,aloussi, Y. U. Han, M. S. Lesniak, "Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors," Journal of Neurosurgery, vol. 105, no. 3, pp. 430-437, 2006.
43. T. Strojnik, R. Kavalar, I. Zajc, E. P. Diamandis, K. Oikonomopoulou, T. T. Lah, "Prognostic impact of CD68 and kallikrein 6 in human glioma," Anticancer Research, vol. 29, no. 8, pp. 3269-3279, 2009.
44. D. S. Markovic, K. Vinnakota, S. Chirasani et al., "Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 30, pp. 12530-12535, 2009.
45. K. S. Siveen and G. Kuttan, "Role of macrophages in tumour progression," Immunology Letters, vol. 123, no. 2, pp. 97-102, 2009.
46. M. R. Young, M. Newby, H. T. Wepsic, "Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors," Cancer Research, vol. 47, no. 1, pp. 100-105, 1987.
47. A. H. Zea, P. C. Rodriguez, M. B. Atkins et al., "Arginaseproducing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion," Cancer Research, vol. 65, no. 8, pp. 3044-3048, 2005.
48. P. Filipazzi, R. Valenti, V. Huber et al., "Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocytemacrophage colony-stimulation factor-based antitumor vaccine," Journal of Clinical Oncology, vol. 25,no. 18,pp. 2546-2553, 2007.
49. J. S. Ko, A. H. Zea, B. I. Rini et al., "Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients," Clinical Cancer Research, vol. 15, no. 6, pp. 2148-2157, 2009.
50. B. Raychaudhuri, P. R. J. Ireland, J. Ko et al., "Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma," Neuro-Oncology, vol. 13, no. 6, pp. 591-599, 2011.
51. A. Mazzoni, V. Bronte, A. Visintin et al., "Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism," The Journal of Immunology, vol. 168, no. 2, pp. 689-695, 2002.
52. D. H. Munn and A. L. Mellor, "IDO and tolerance to tumors," Trends in Molecular Medicine, vol. 10, no. 1, pp. 15-18, 2004.
53. P. C. Rodŕguez and A. C. Ochoa, "Arginine regulation by myeloid derived suppressor cells and tolerance in cancer:mechanisms and therapeutic perspectives," Immunological Reviews, vol. 222, no. 1, pp. 180-191, 2008.
54. W. Jia, C. Jackson-Cook, M. R. Graf, "Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model," Journal of Neuroimmunology, vol. 223, no. 1-2, pp. 20-30, 2010.
55. D. Dubinski, J. Wölfer, M. Hasselblatt et al., "CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients," Neuro-Oncology, 2015.
56. C. Hao, I. F. Parney, W. H. Roa, J. Turner, K. C. Petruk, D. A. Ramsay, "Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence ofTh1,Th2andTh3 cytokine dysregulation," Acta Neuropathologica, vol. 103, no. 2, pp. 171-178, 2002.
57. A. M. Bender, L. S. Collier, F. J. Rodriguez et al., "Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas," Cancer Research, vol. 70, no. 9, pp. 3557-3565, 2010.
58. G. G. Gomez and C. A. Kruse, "Mechanisms of malignant glioma immune resistance and sources of immunosuppression," GeneTherapy and Molecular Biology, vol. 10, no. 1, pp. 133-146, 2006.
59. J. Han, C. A. Alvarez-Breckenridge, Q.-E. Wang, J. Yu, "TGF-signaling and its targeting for glioma treatment," American Journal of Cancer Research, vol. 5, no. 3, pp. 945-955, 2015.
60. J. T. Jordan, W. Sun, S. F. Hussain, G. DeAngulo, S. S. Prabhu, A. B. Heimberger, "Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy," Cancer Immunology, Immunotherapy, vol. 57, no. 1, pp. 123-131, 2008.
61. S. V. Maru, K. A. Holloway, G. Flynn et al., "Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation," Journal of Neuroimmunology, vol. 199, no. 1-2, pp. 35-45, 2008.
62. B. D. Choi, P. E. Fecci, J. H. Sampson, "Regulatory T cells move in when gliomas say 'I DO'," Clinical Cancer Research, vol. 18, no. 22, pp. 6086-6088, 2012.
63. K. Saito, S. P. Markey, M. P. Heyes, "Chronic effects of-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of C57BL6 mice," Brain Research, vol. 546, no. 1,pp. 151-154, 1991.
64. J. Wei, A. Wu, L.-Y. Kong et al., "Hypoxia potentiates gliomamediated immunosuppression," PLoS ONE, vol. 6, no. 1,Article ID e16195, 2011.
65. E. Maderna, A. Salmaggi, C. Calatozzolo, L. Limido, B. Pollo, "Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic)molecule expression are related with tumor grade and may provide prognostic information," Cancer Biology &Therapy, vol. 6, no. 7, pp. 1018-1024, 2007.
66. A. D. Norden, J. Drappatz, P. Y. Wen, "Antiangiogenic therapies for high-grade glioma," Nature Reviews Neurology, vol. 5, no. 11, pp. 610-620, 2009.
67. P. Carmeliet, Y. Dor, J.-M. Herbert et al., "Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis," Nature, vol. 394, no. 6692, pp. 485-490, 1998.
68. M. J. Gray, J. Zhang, L. M. Ellis et al., "HIF-1, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas," Oncogene, vol. 24, no. 19, pp. 3110-3120, 2005.
69. J. E. Jung, H. G. Lee, I. H. Cho et al., "STAT3 is a potential modulator ofHIF-1-mediatedVEGF expression in human renal carcinoma cells," The FASEB Journal, vol. 19, no. 10, pp. 1296-1298, 2005.
70. J. Ben-Shoshan, S. Maysel-Auslender, A. Mor, G. Keren, J. George, "Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1," European Journal of Immunology, vol. 38, no. 9, pp. 2412-2418, 2008.
71. Y. C. Ooi, P. Tran,N. Ung et al., "The role of regulatory T-cells in glioma immunology," Clinical Neurology and Neurosurgery, vol. 119, pp. 125-132, 2014.
72. M. Kortylewski and H. Yu, "Role of Stat3 in suppressing antitumor immunity," Current Opinion in Immunology, vol. 20, no. 2, pp. 228-233, 2008.
73. M. Orozco-Morales, F. J. Sánchez-Garcá, I. Golán-Cancela et al., "RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells," Cancer Cell International, vol. 15, article 57, 2015.
74. N. Umemura, M. Saio, T. Suwa et al., "Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics," Journal of Leukocyte Biology, vol. 83, no. 5, pp. 1136-1144, 2008.
75. K. L. Black, K. Chen, D. P. Becker, J. E. Merrill, "Inflammatory leukocytes associated with increased immunosuppression by glioblastoma," Journal of Neurosurgery, vol. 77, no. 1, pp. 120-126, 1992.
76. B. Thaci, A. U. Ahmed, I. V. Ulasov et al., "Depletionofmyeloidderived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma," Cancer Gene Therapy, vol. 21, no. 1, pp. 38-44, 2014.
77. E. A. Vega, M. W. Graner, J. H. Sampson, "Combating immunosuppression in glioma," Future Oncology, vol. 4, no. 3, pp. 433-442, 2008.
78. M. Orozco-Morales, F.-J. Sánchez-Garcá, P. Guevara-Salazar et al., "Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin," Journal of Cancer Research and Clinical Oncology, vol. 138, no. 1, pp. 23-33, 2012.
79. R. Magaña-Maldonado, K. Manoutcharian, N. Y. Hernández-Pedro et al., "Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma," Journal of Cancer Research and Clinical Oncology, vol. 140, no. 2, pp. 291-301, 2014.
80. J. H. Sampson,R. J. Schmittling,G. E. Archer et al., "Apilot study of IL-2R blockade during lymphopenia depletes regulatory Tcells and correlates with enhanced immunity in patients with glioblastoma," PLoS ONE, vol. 7, no. 2,Article ID e31046, 2012.
81. A. T. Parsa, J. S. Waldron, A. Panner et al., "Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma," Nature Medicine, vol. 13,no. 1, pp. 84-88, 2007.
82. J. Zeng, A. P. See, J. Phallen et al., "Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas," International Journal of Radiation Oncology Biology Physics, vol. 86, no. 2, pp. 343-349, 2013.
83. D. A. Wainwright, I. V. Balyasnikova, A. L. Chang et al., "IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival," Clinical Cancer Research, vol. 18, no. 22, pp. 6110-6121, 2012.
84. L. Zhang, D. Alizadeh, M. van Handel, M. Kortylewski, H. Yu, B. Badie, "Stat3 inhibition activates tumormacrophages and abrogates glioma growth in mice," Glia, vol. 57, no. 13, pp. 1458-1467, 2009.
85. J. Wei, F. Wang, L.-Y. Kong et al., "miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma," Cancer Research, vol. 73, no. 13, pp. 3913-3926, 2013.
86. D. Zhao, D. Alizadeh, L. Zhang et al., "Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity," Clinical Cancer Research, vol. 17, no. 4, pp. 771-782, 2011.